Ulcesep

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulcesep

Quick Facts

Property Description
Active ingredient Omeprazole (a Substituted Benzimidazole)
Form Capsules or Tablets (Delayed-release)
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acidity
Origin Synthetic compound

Ulcesep is a fundamental medication defined by its ability to profoundly and sustainably reduce the production of acid in the stomach. Its identity is centered on the active chemical component, Omeprazole, which is a synthetic compound widely used in the management of gastric acid-related disorders.


What Type of Medicine is Ulcesep (Omeprazole)?

Ulcesep belongs to the highly effective pharmacological class known as Proton Pump Inhibitors (PPIs), a class clinically recognized for its efficacy in acid suppression. This classification identifies the drug as a single-ingredient product whose active substance, Omeprazole, is a Substituted Benzimidazole compound. The PPI class mechanism works by causing the irreversible inhibition of the final stage of acid creation: the enzyme system known as the H^+K^+-ATPase, or the gastric acid pump. This action leads to long-lasting control of acid secretion, which is crucial for managing acid-related issues.

Ulcesep's Pharmaceutical Form and General Purpose

Ulcesep is manufactured for Oral administration, typically supplied as Capsules or Tablets with specialized coatings. These forms are engineered as delayed-release or utilize enteric-coated technology. This pharmaceutical innovation is necessary because the active ingredient, Omeprazole, is acid-labile—it would be degraded and rendered ineffective by stomach acid without this protection. The delayed-release mechanism ensures the drug is preserved through the stomach and released into the small intestine for proper absorption. The overarching general purpose of Ulcesep is to maintain a sustained reduction of gastric acidity. This prolonged acid suppression is vital for mitigating irritation to the digestive lining, thereby creating an environment conducive to the healing of affected tissues.

Regulatory References

  1. MedlinePlus

What side effects are possible with Ulcesep?

Possible Side Effects and Safety Information

The safety profile of Ulcesep (omeprazole) is formally documented in government regulatory sources, which classify adverse reactions based on their observed frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

The most frequently reported side effects are classified as Common, affecting primarily the gastrointestinal system and the nervous system. These include headache, abdominal pain, diarrhea, flatulence, constipation, nausea, and vomiting. Reactions classified as Uncommon include dizziness, insomnia, and the potential for increased liver enzyme levels.

Classification Examples of Affected Systems
Common Gastrointestinal, Nervous System
Uncommon Nervous System, Hepatobiliary, Musculoskeletal

Serious Adverse Reactions and Safety Patterns

Official labeling highlights the potential for Serious Adverse Reactions, including life-threatening Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are classified as Rare or Very Rare. Acute Interstitial Nephritis (TIN) is also documented as a possible severe reaction affecting the kidneys.

Safety notes tied to duration of exposure are explicitly stated in regulatory texts. Long-term daily use (typically exceeding one year) is associated with an increased risk of bone fractures of the hip, wrist, or spine, and the potential for low serum magnesium (Hypomagnesaemia). Additionally, daily use over three years may be associated with Vitamin B12 deficiency.

For specific populations, safety considerations are noted for patients with Hepatic Impairment, where a rare risk of encephalopathy exists in those with pre-existing severe liver disease. Response to the medicine does not exclude the potential presence of gastric malignancy, a key safety limitation noted in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose scenarios for Ulcesep (Omeprazole) based on reported cases. Overdosage is considered rare, and the documented signs have generally been transient (short-lived) with no serious clinical outcome reported in acute cases.


Documented Manifestations and Required Actions

Domain Official Regulatory Statement
Documented Manifestations Symptoms reported include confusion, drowsiness, blurred vision, tachycardia (rapid heart rate), nausea, diaphoresis (sweating), flushing, headache, and dry mouth.
Emergency Requirement Individuals must seek emergency medical attention immediately or contact a Poison Help line upon suspected overdose.
Antidote Availability No specific antidote is known for Omeprazole overdosage.
Required Management Treatment should be symptomatic and supportive.

Regulatory Context for Overdose Management

Due to the drug's properties, Omeprazole is extensively protein bound and is therefore not readily dialyzable, which informs the management strategy. The need to seek emergency medical attention is a critical, regulator-mandated step to ensure that clinical professionals can initiate appropriate supportive care and monitoring for any of the documented manifestations.

Therapeutic Uses of Ulcesep

What Ulcesep Treats: Main Uses and Benefits

Ulcesep is primarily used for the supportive management of symptoms associated with conditions characterized by excess stomach acid. Its role is to contribute to improved day-to-day comfort and stability during periods of heightened symptoms. This type of medication is used to prevent and treat symptoms such as heartburn, acid indigestion, and sour stomach.


Easing Common Digestive Discomfort

Ulcesep helps address groups of symptoms related to heightened physiological activity in the stomach. This makes it relevant when short-term symptom management is appropriate for symptoms that may become intense or disruptive. The medication supports patients during difficult episodes and is commonly used to help with symptoms that cluster into patterns requiring supportive management.

“May assist with symptoms related to episodic or fluctuating manifestations of digestive discomfort.”

Quick Fact: May help ease symptoms of Heartburn & Indigestion

Supportive Relief for Recurrent Symptom Patterns

The medicine is relevant in conditions involving episodic or fluctuating manifestations related to acid issues. It is considered relevant in situations where symptoms may create noticeable physiological strain and require additional symptomatic support. Ulcesep may help support functional stability by offering temporary assistance in symptom stabilization, particularly when symptoms become more noticeable and disruptive and interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information on Famotidine

Eligibility and Restrictions for Use

Ulcesep (Omeprazole) is subject to specific eligibility rules defined by government regulatory agencies. These rules establish the approved user groups and list populations that are strictly prohibited from using the medication.


Contraindicated Populations

Use of Ulcesep is absolutely prohibited for the following groups, as stated in regulatory labeling:

  • Patients with known hypersensitivity to omeprazole, to the drug class of substituted benzimidazoles, or to any component of the formulation.
  • Patients who are receiving co-treatment with rilpivirine or nelfinavir-containing products.

Age-Related Eligibility and Limitations

Age Group Eligibility Status
Adults (18+ years) Established use for all approved label indications.
Children (1 to 16 years) Established use for conditions like symptomatic GERD and maintenance of Erosive Esophagitis (EE).
Infants (ge 1 month) Established use for the treatment of EE, but safety and effectiveness are not established for infants younger than one month of age.
Older Adults No general dose adjustment is required, but labeling notes they may be more sensitive to the medicine's effects.

Conditional Use and Restrictions

  • Hepatic Impairment (Liver Problems): Use is conditional; regulators recommend that dose reduction be considered in patients with liver problems, particularly for long-term use, due to the drug's altered metabolism.
  • Pregnancy and Lactation: Use during pregnancy is generally considered acceptable, as large-scale epidemiological data do not indicate an increased risk of major birth defects. Use while breastfeeding is also compatible, as low levels in breast milk are not expected to harm the infant.
  • Gastric Malignancy: Before starting treatment, patients must be assessed to exclude the presence of gastric malignancy, as symptomatic relief does not rule out the condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ulcesep (Omeprazole) has officially documented interactions that primarily stem from two pharmacological actions: its effect on gastric pH elevation and its role as an inhibitor of the CYP2C19 liver enzyme. Regulatory information specifies combinations that are prohibited or require strict administration restrictions due to changes in drug exposure. Co-administration is contraindicated with Rilpivirine-containing products and Nelfinavir, as Ulcesep significantly reduces the plasma concentrations of these antiretroviral agents. Due to CYP2C19 inhibition, co-administration with the antiplatelet medicine Clopidogrel should be avoided, as it diminishes the formation of Clopidogrel's active metabolite.

Interaction Type Interacting Substance Outcome Described in Regulatory Documents
Reduced Absorption (pH-dependent) Atazanavir, Ketoconazole, Iron Salts Decreased plasma concentration and therapeutic efficacy.
Increased Absorption (pH-dependent) Digoxin, Saquinavir Potential for increased systemic exposure and toxicity risk.
Metabolic Inhibition Cilostazol, Tacrolimus Increased systemic exposure of the co-administered drug.

Furthermore, the drug's interaction profile includes specific timing rules: Ulcesep must be temporarily stopped for at least 14 days prior to assessing Chromogranin A (CgA) levels, a necessary step to prevent diagnostic interference. Strong CYP inducers like Rifampin and the herbal product St. John's Wort are also listed as substances that should be avoided due to the potential for reduced Omeprazole concentrations. These restrictions ensure use within the established regulatory framework.

Mechanism of Action

Ulcesep (Esomeprazole) functions as a Proton Pump Inhibitor (PPI), selectively targeting the gastric parietal cells. Upon systemic absorption, the compound is delivered to the secretory canaliculi of these cells, where the low acidic pH facilitates its conversion into the active sulfenamide derivative. This derivative acts as an irreversible non-competitive inhibitor of the hydrogen-potassium ATPase (H^+/K^+-ATPase) enzyme system, commonly known as the proton pump.

The active sulfenamide covalently binds to sulfhydryl groups on specific cysteine residues of the H^+/K^+-ATPase alpha-subunit. This molecular interaction leads to the structural and functional inactivation of the enzyme. Since the proton pump executes the final common step for H^+ ion secretion into the gastric lumen, its inhibition blocks both basal and stimulated acid production, irrespective of the upstream physiological stimulus. The resulting downstream cascade is a sustained, long-term system-level reduction in gastric fluid acidity, increasing the intragastric pH.

Dosage and Administration Information

Ulcesep's administration is governed by specific instructions prescribed in its usage guidelines to ensure the active ingredient is protected from gastric acid and properly absorbed.


The primary route of administration is Oral, typically using delayed-release capsules or tablets. For patients where the oral route is inappropriate, the Intravenous (IV) route is approved as a temporary alternative. Oral formulations must be taken before a meal, preferably in the morning.

Official Dosing and Administration

The medicine's full efficacy relies on the integrity of the delayed-release form: Capsules and tablets must be swallowed whole and must not be crushed or chewed. If swallowing the capsule intact is difficult, the contents (pellets) may be mixed with a spoonful of soft, cool applesauce and swallowed immediately.

Dosing Pattern Requirement
Standard Dosing Typically 20 mg to 40 mg once daily for initial treatment and maintenance.
High-Dose Frequency Total daily dosages exceeding 80 mg (e.g., in hypersecretory conditions) must be administered in divided doses.
Special Populations Dose reduction is generally recommended for patients with hepatic impairment; no adjustment is typically needed for patients with renal impairment.

Dosing for pediatric patients is prescribed using weight-based dosing. Treatment duration varies from fixed short-term courses (e.g., 4–8 weeks) to indefinite administration for certain chronic conditions.

Missed Dose Guidance

If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose must be skipped. Do not take a double dose.

Recent Clinical Evidence

Ulcesep: Recent Clinical Evidence

Recent clinical studies and meta-analyses support the use of Ulcesep (containing the active substance omeprazole) as an effective agent for reducing gastric acid secretion across multiple upper gastrointestinal disorders. Findings consistently indicate that it promotes the healing of erosive esophagitis (EE) and provides relief from symptoms associated with Gastroesophageal Reflux Disease (GERD), such as heartburn and acid regurgitation.

Efficacy in Ulcer and H. pylori Eradication

Clinical data demonstrates Ulcesep's role in the short-term treatment and healing of duodenal and gastric ulcers. For ulcers associated with Helicobacter pylori infection, Ulcesep is administered as part of a combination therapy with antibiotics. Studies show that this triple or quadruple regimen significantly aids in H. pylori eradication, which subsequently reduces the risk of ulcer recurrence.

Comparative Trial Outcomes

In trials comparing Ulcesep to certain older classes of acid-reducing medications, such as histamine H2-receptor antagonists, Ulcesep consistently demonstrated a greater and more sustained suppression of gastric acid production. For instance, in the long-term maintenance of EE healing, trials reported a significantly higher percentage of patients remaining in remission with Ulcesep compared to the comparator.

Long-Term Research and Safety Observations

Long-term observational research has been crucial for characterizing the safety profile of the proton pump inhibitor class to which Ulcesep belongs. Post-marketing surveillance and larger studies have drawn attention to potential associations with extended use, including the risk of vitamin B12 deficiency, hypomagnesemia, and an increased risk of specific bone fractures of the hip, wrist, or spine. These findings highlight the need for periodic re-evaluation by healthcare providers when long-term therapy is required.

Frequently Asked Questions (FAQ)

Common questions about Ulcesep (FAQ)


Q: Does Ulcesep affect my ability to drive or operate machinery?

According to the official product information, adverse reactions such as dizziness, drowsiness, insomnia, or visual disturbances are listed. Regulatory warnings indicate that caution should be exercised regarding driving or operating machinery if you experience these effects.


Q: How does Ulcesep compare to Cimetidine or Tagamet?

Clinical trials and official information have indicated that Ulcesep, a Proton Pump Inhibitor, demonstrated a more sustained suppression of gastric acid production compared to older classes of acid-reducing medicines, such as H2-receptor antagonists (the class Cimetidine belongs to). This is due to Ulcesep’s mechanism of blocking the final step of acid production.


Q: How long does Ulcesep stay in your system after you stop taking it?

Regulatory documents indicate that the elimination half-life of Ulcesep from the blood plasma is relatively short, typically reported to be approximately 0.5 to 3 hours. However, the therapeutic effect of reducing acid production continues well beyond the elimination of the drug from the plasma, due to its mechanism of action.


Q: Is Ulcesep a prescription-only drug in most places?

The active ingredient in Ulcesep, omeprazole, is available in some countries in lower strengths as an Over-the-Counter (OTC) medicine for temporary relief of certain acid-related symptoms. Higher doses or treatment for specific long-term conditions typically require a prescription.


Q: Can Ulcesep be crushed or split if it's hard to swallow?

Official prescribing information states that the tablets or capsules should not be crushed, chewed, or split, as this is necessary to protect the medicine from stomach acid. If directed by a healthcare provider, the contents (pellets) of the capsule may be mixed with a spoonful of soft, cool applesauce and swallowed right away.


Q: Does Ulcesep interact with supplements like St. John's Wort or fish oil?

Regulatory documents list the herbal product St. John's Wort as a substance that may reduce the concentration of Ulcesep in the body and is generally listed as one to use with caution. The official product information does not contain specific warnings regarding an interaction with common supplements like fish oil.


Q: Are there known allergic reactions to look out for with Ulcesep?

Yes, hypersensitivity (allergic reaction) to Ulcesep or its drug class is a contraindication. While rare, serious reactions like Severe Cutaneous Adverse Reactions (SCARs) have been reported. Other signs of allergic reactions can include rash, hives, swelling, or difficulty breathing or swallowing.


Q: How is Ulcesep different from antacids like Tums or Gaviscon?

Antacids work by immediately neutralizing existing acid in the stomach for quick, temporary relief. Ulcesep, as a Proton Pump Inhibitor, works differently by blocking the body’s acid-producing pumps at the cellular level. This provides a sustained, long-term reduction in acid secretion, which is vital for the healing of affected tissues.


Q: Does Ulcesep interact with alcohol?

Regulatory drug labels generally do not include a specific contraindication for using alcohol with Ulcesep. However, consuming alcohol is generally known to increase stomach acid production, which may counteract the medicine's effect of reducing acid, potentially worsening the underlying condition.


Q: Why does the packaging for Ulcesep mention liver function?

The medicine is extensively processed by the liver. Regulatory documents advise that for patients with significant liver (hepatic) problems, a dose reduction should be considered because the drug may stay in the body longer, potentially increasing exposure.


Q: What should I do if I accidentally take too much Ulcesep?

In the event of an overdose, regulatory information emphasizes the importance of seeking immediate medical assistance. You should contact a poison control center or seek emergency medical care right away. Reported symptoms of overdose have included confusion, blurred vision, and headache.


Q: Is the core ingredient in Ulcesep found in any other medicines?

Yes, the active ingredient in Ulcesep is omeprazole. This is the same active chemical component found in many other branded and generic Proton Pump Inhibitors (PPIs) that are used to treat acid-related conditions.


Q: Can Ulcesep affect mood or cause anxiety?

The official product information lists rare adverse reactions affecting the nervous system and psychiatric health. These can include effects such as insomnia, confusion, and depression. Post-marketing reports have also included instances of anxiety.

How should Ulcesep be stored and disposed of?

How to Store and Dispose of Ulcesep (Omeprazole)

Ulcesep must be stored under specific environmental conditions to protect the integrity of its delayed-release formulation.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), permitting excursions between 15 C and 30 C.
Protection Protect from moisture; do not store in humid areas like a bathroom. Do not freeze.
Container Keep in the original container, tightly closed. If bottled, use within 3 months after first opening.
Child Safety Keep out of the sight and reach of children.

Disposal Requirements

Unused or expired Ulcesep must not be thrown into household trash or wastewater. Consult a pharmacist for instructions on how to properly dispose of any medicines you no longer use, following local pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcesep found in:

A-Z Index: